You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

lipoprotein(a)

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Elevated Lipoprotein(a) Level, Coronary Artery Disease, Drug-Eluting Stent Trial in Beijing (24 Months DAPT, 12 Months DAPT)

Not yet recruiting
  • Elevated Lipoprotein(a) Level
  • +3 more
  • 24 Months DAPT
  • 12 Months DAPT
  • Beijing, Beijing, China
    Fuwai Hospital, National Center for Cardiovascular Diseases, Chi
Aug 26, 2023

Lipoprotein(a) and Endogenous Fibrinolysis in Atherosclerotic

Recruiting
  • Atherosclerosis
  • Aortic Valve Disease
  • Thrombotic assessment
  • Measurement of Lp(a)
  • Stevenage, United Kingdom
    East and North Herts NHS Trust
Nov 6, 2023

Cardiovascular Disease Trial in Saint-Denis (blood lipoprotein (a) test)

Recruiting
  • Cardiovascular Disease
  • blood lipoprotein (a) test
  • Saint-Denis, France
    Centre Hospitalier Universitaire de la Réunion
Aug 29, 2022

Cardiovascular Diseases, Atherosclerosis, Lipoprotein(a) Trial (SLN360, Placebo)

Not yet recruiting
  • Cardiovascular Diseases
  • +2 more
  • (no location specified)
Sep 12, 2022

Lymphedema Trial in Nice (lipoprotein (a))

Not yet recruiting
  • Lymphedema
  • lipoprotein (a)
  • Nice, Centre Antoine Lacassagne, France
    CAUSERET Marion
Jul 19, 2023

Thrombogenicity of Lipoprotein A: Laboratory Study Defining

Not yet recruiting
  • Cardiovascular Disease and Lipid Disorders
  • Cardiac Disease
  • Non-interventional
  • Middlesbrough, Teesside, United Kingdom
    South Tees Hospitals NHS FT
Apr 14, 2022

Acute Coronary Syndrome, Lipoprotein Disorder, Acute Myocardial Infarction Trial in Caserta

Recruiting
  • Acute Coronary Syndrome
  • +3 more
    • Caserta, Italy
      AORN S. Anna e S. Sebastiano
    Aug 9, 2022

    Aortic Stenosis Trial (Pelacarsen (TQJ230) 80mg, Matching )

    Not yet recruiting
    • Aortic Stenosis
    • Pelacarsen (TQJ230) 80mg
    • Matching placebo
    • (no location specified)
    Dec 2, 2022

    Elevated Serum Lipoprotein(a) Trial in Hong Kong (Olpasiran)

    Completed
    • Elevated Serum Lipoprotein(a)
    • Hong Kong, HK, Hong Kong
      Queen Mary Hospital
    Mar 30, 2022

    Cardiovascular Diseases Trial in Shatin (TQJ230, Placebo)

    Active, not recruiting
    • Cardiovascular Diseases
    • Shatin, Hong Kong
      The Chinese University of Hong Kong
    Sep 16, 2022

    Hyperlipoproteinemia(a) Trial (Pelacarsen (TQJ230) 80 mg s.c., Corresponding Placebo)

    Not yet recruiting
    • Hyperlipoproteinemia(a)
    • Pelacarsen (TQJ230) 80 mg s.c.
    • Corresponding Placebo
    • (no location specified)
    Mar 22, 2022

    Hyperlipidemias, Dyslipidemias Trial (Obicetrapib)

    Not yet recruiting
    • Hyperlipidemias
    • Dyslipidemias
    • (no location specified)
    Aug 2, 2023

    Cholesterol; Metabolic Disorder, Lipoproteinemia Trial in Nantes (infusion of tracer [5,5,5-2H3] -L-leucine)

    Completed
    • Cholesterol; Metabolic Disorder
    • Lipoproteinemia
    • infusion of tracer [5,5,5-2H3] -L-leucine
    • Nantes, France
      Nantes University Hospital
    Feb 22, 2022

    Lp(a) With CCTA Assessed Parameters and Clinical Outcomes

    Recruiting
    • Coronary Artery Disease
    • Coronary CTA
    • Shanghai, China
      Shanghai Zhongshan Hospital
    Apr 4, 2022

    Primary Hypercholesterolemia or Mixed Dyslipidemia Trial (Inclisiran, Matching Placebo for Inclisiran)

    Not yet recruiting
    • Primary Hypercholesterolemia or Mixed Dyslipidemia
    • (no location specified)
    May 24, 2023

    Elevated Low-Density Lipoprotein Cholesterol Trial in Herston, Adelaide, Melbourne (SNK-396 - SAD cohort, SNK-396 - MAD Cohort)

    Recruiting
    • Elevated Low-Density Lipoprotein Cholesterol
    • SNK-396 - SAD cohort
    • SNK-396 - MAD Cohort
    • Herston, Queensland, Australia
    • +2 more
    Jun 6, 2023

    To Reduce the LDL-C Level in Hypercholesteremia Adult Patients, Combination for Subgroup High LDL-c Patients With Other

    Not yet recruiting
    • To Reduce the LDL-C Level in Hypercholesteremia Adult Patients
    • Combination for Subgroup High LDL-c Patients With Other Comorbidities
    • RN0191 INJECTION
    • (no location specified)
    Jun 14, 2023

    Hyperlipidemias, Dyslipidemias, Elevated Lp(a) Trial in Worldwide (SLN360, Placebo)

    Recruiting
    • Hyperlipidemias
    • +2 more
    • Jacksonville, Florida
    • +6 more
    Mar 18, 2022

    OLOMAX for Blood Pressure and Low-density Lipoprotein

    Recruiting
    • Hypertension
    • Dyslipidemias
    • Olmesartan Medoxomil/ Amlodipine Besylate/ Rosuvastatin Ca
    • Seoul, Korea, Republic of
      Seoul St.Mary's Hospital
    Dec 13, 2022

    Lipoprotein-associated Phospholipase A2 in Type 2 Diabetes

    Completed
    Has Results
    • Type2 Diabetes
      • (no location specified)
      Apr 12, 2022

      Hyper-low-density Lipoprotein (LDL) Cholesterolemia Trial in Izumisano-shi (180mg of ETC-1002(bempedoic acid), Placebo)

      Recruiting
      • Hyper-low-density Lipoprotein (LDL) Cholesterolemia
      • 180mg of ETC-1002(bempedoic acid)
      • Placebo
      • Izumisano-shi, Japan
        Rinku General Medical Center
      Jan 4, 2023

      Coronary Artery Diseasse Trial in Seoul (fixed high potent statin therapy, targeted LDL-C goal statin)

      Active, not recruiting
      • Coronary Artery Diseasse
      • fixed high potent statin therapy
      • targeted LDL-C goal statin
      • Seoul, Korea, Republic of
        Division of Cardiology, Department of Internal Medicine, Yonsei
      Jul 19, 2022

      Lipoprotein Disorder Trial in Worldwide (LY3473329, Placebo)

      Recruiting
      • Lipoprotein Disorder
      • Liverpool, New South Wales, Australia
      • +46 more
      Jan 18, 2023

      Hemorrhagic Stroke Trial in Shenyang (DELP)

      Recruiting
      • Hemorrhagic Stroke
      • DELP
      • Shenyang, China
        Department of Neurology, General Hospital of Northern Theater Co
      Jan 27, 2022

      Hyper-low-density Lipoprotein (LDL) Cholesterolemia Trial in Izumisano-shi (180mg of ETC-1002(bempedoic acid))

      Recruiting
      • Hyper-low-density Lipoprotein (LDL) Cholesterolemia
      • 180mg of ETC-1002(bempedoic acid)
      • Izumisano-shi, Japan
        Rinku General Medical Center
      Jan 13, 2023